Research
Revenio: All cylinders are hot
All of Revenio’s market and product areas are performing strongly based on the Q1 report, and we expect strong growth figures also in Q2 and Q3. At the same time, the company is building a long-term growth path with effective investments. In our opinion, the increase in RBT tonometers’ market share, imaging devices, HOME product, and software business provide preconditions for strong growth over the next 10 years.
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
Read more on company pageKey Estimate Figures2021-04-25
| 2020 | 21e | 22e | |
|---|---|---|---|
| Revenue | 61.1 | 79.3 | 102.5 |
| growth-% | 23.4 % | 29.9 % | 29.1 % |
| EBIT (adj.) | 19.2 | 27.5 | 35.5 |
| EBIT-% (adj.) | 31.4 % | 34.7 % | 34.7 % |
| EPS (adj.) | 0.58 | 0.83 | 1.04 |
| Dividend | 0.32 | 0.40 | 0.55 |
| Dividend % | 0.6 % | 3.1 % | 4.3 % |
| P/E (adj.) | 86.6 | 15.5 | 12.4 |
| EV/EBITDA | 61.5 | 11.9 | 8.7 |
Forum discussions
